Compare MCBS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | CTMX |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.6M | 596.2M |
| IPO Year | 2019 | 2015 |
| Metric | MCBS | CTMX |
|---|---|---|
| Price | $26.65 | $4.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $31.00 | $6.50 |
| AVG Volume (30 Days) | 51.6K | ★ 3.8M |
| Earning Date | 10-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | 11.15 | ★ 50.22 |
| EPS | ★ 2.59 | 0.24 |
| Revenue | ★ $147,349,000.00 | $113,631,000.00 |
| Revenue This Year | $18.90 | N/A |
| Revenue Next Year | $27.50 | N/A |
| P/E Ratio | ★ $10.29 | $17.87 |
| Revenue Growth | ★ 8.69 | N/A |
| 52 Week Low | $24.24 | $0.40 |
| 52 Week High | $35.45 | $4.62 |
| Indicator | MCBS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 63.31 |
| Support Level | $25.84 | $3.42 |
| Resistance Level | $27.10 | $4.25 |
| Average True Range (ATR) | 0.65 | 0.28 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 85.42 | 85.85 |
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.